Read by QxMD icon Read

Lupus disease activity

Mai Kawazoe, Kaichi Kaneko, Zento Yamada, Shotaro Masuoka, Satoshi Mizutani, Soichi Yamada, Kotaro Shikano, Hiroshi Sato, Makoto Kaburaki, Sei Muraoka, Shinichi Kawai, Toshihiro Nanki
OBJECTIVES: To assess the renal and non-renal efficacy of mycophenolate mofetil (MMF) in Japanese patients with systemic lupus erythematosus (SLE). METHODS: We conducted a retrospective study to assess the renal and non-renal efficacies of MMF in Japanese patients with systemic lupus erythematosus (SLE). We analyzed 14 patients with lupus nephritis (LN) who were given MMF, and 13 patients who received monthly intravenous cyclophosphamide (IVCY) as induction therapy, and a further 19 patients without LN who were treated with MMF, and 13 patients who took tacrolimus (TAC) to reduce glucocorticoid dosages...
February 18, 2019: Clinical Rheumatology
B Costa Rodrigues, M Ignacchiti Lacerda, G R Ramires de Jesús, Flávia Cunha Dos Santos, N Ramires de Jesús, R A Levy, E Mendes Klumb
OBJECTIVE: To analyze the impact of different classes of lupus nephritis as risk variables for maternal and fetal adverse outcomes in a cohort of pregnant lupus patients. METHODS: This is a cohort study with retrospective and prospective data collection, conducted at the University Hospital of State University of Rio de Janeiro, Brazil, from 2011 to 2016. A total of 147 pregnancies of 137 systemic lupus erythematosus patients of whom 66 had lupus nephritis were included...
February 18, 2019: Lupus
Yashaar Chaichian, Daniel J Wallace, Michael H Weisman
Despite advances in understanding systemic lupus erythematosus (SLE) pathogenesis, most clinical trials of new targeted therapies have been met with disappointment. The type I IFN pathway is believed to play an important role in SLE, and the proposed involvement of this pathway helps explain the frustration behind the failure at targeting either IFN-α or the type 1 IFN receptor itself. In this issue of the JCI, Furie et al. report on an intriguing phase 1b study that demonstrates an approach for inhibiting this pathway in the skin using an mAB (BIIB059) that targets the blood DC antigen 2 (BDCA-2) receptor on plasmacytoid DCs (pDCs)...
February 18, 2019: Journal of Clinical Investigation
Nidal Karim Al-Rahal
Background: Consanguineous marriage is defined as inbreeding between second cousins or closer. In such families there will be a potential increase in the autosomal recessive traits with its lethal effect, with an increased risk of morbidity and mortality in the new generation. Inherited bleeding disorders (InBDs) are rare complicated diseases, difficult and expensive to treat, the defect usually due to quantitative or qualitative deficiency of clotting factors, platelets or fibrinolysis. This study attempts to assess the diversity, the frequency and the clinical features of inherited bleeding disorders (InBDs) in central part of Iraq and to determine the state of consanguineous marriage...
October 1, 2018: International Journal of Hematology-oncology and Stem Cell Research
Sandra Gofinet Pasoto, Victor Adriano de Oliveira Martins, Eloisa Bonfa
Systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) may coexist, and they are chronic complex disorders, with an autoimmune background, multifactorial etiology, multiple circulating autoantibodies, and variable prognosis. The prominent feature of SS is the impairment of the lacrimal and salivary glands leading to sicca symptoms. This disease may be classified as primary Sjögren's syndrome (pSS), or secondary Sjögren's syndrome (sSS) since it is often associated to other autoimmune disorders, principally SLE, rheumatoid arthritis, and systemic sclerosis...
2019: Open Access Rheumatology: Research and Reviews
Di Long, Yongjian Chen, Haijing Wu, Ming Zhao, Qianjin Lu
Interleukin-21 (IL-21), an autocrine cytokine predominantly produced by follicular helper T (Tfh) and T helper 17 (Th17) cells, has been proven to play an important role in the immune system, for example, by promoting proliferation and the development of Tfh and Th17 cells, balancing helper T cell subsets, inducing B cell generation and differentiation into plasma cells, and enhancing the production of immunoglobulin. These effects are mainly mediated by activation of the JAK/STAT, MAPK and PI3K pathways...
February 14, 2019: Journal of Autoimmunity
Adrian Y S Lee, Heinrich Körner
Traditionally, chemokine immunobiology has focused on chemotaxis and the positioning of cells at sites of inflammation and within lymphoid organs. More recently, however, regulation of intricate immune responses has emerged as a function attributed to chemokines and their receptors. One such pair, CCR6 and its chemokine ligand CCL20, has been receiving interest for its potential role in the coordination and regulation of humoral immune responses and in particular, memory responses, at the cellular level. B cells up-regulate CCR6 after activation in secondary lymphoid organs; however, its function is still unclear...
February 8, 2019: Immunobiology
Alexandra Legge, Susan Kirkland, Kenneth Rockwood, Pantelis Andreou, Sang-Cheol Bae, Caroline Gordon, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Daniel J Wallace, Sasha Bernatsky, Ann E Clarke, Joan T Merrill, Ellen M Ginzler, Paul Fortin, Dafna D Gladman, Murray B Urowitz, Ian N Bruce, David A Isenberg, Anisur Rahman, Graciela S Alarcón, Michelle Petri, Munther A Khamashta, M A Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Kristjan Steinsson, Asad A Zoma, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, S Sam Lim, Murat Inanc, Ronald F van Vollenhoven, Andreas Jonsen, Ola Nived, Manuel Ramos-Casals, Diane L Kamen, Kenneth C Kalunian, Soren Jacobsen, Christine A Peschken, Anca Askanase, John G Hanly
OBJECTIVE: To evaluate the properties of a frailty index (FI), constructed using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, as a novel health measure in SLE. METHODS: For this secondary analysis, the baseline visit was defined as the first study visit at which both organ damage (SLICC/ACR Damage Index [SDI]) and health-related quality of life (Short-Form 36 [SF-36]) were assessed. The SLICC-FI was constructed using baseline data...
February 16, 2019: Arthritis & Rheumatology
Daniel J Wallace, Ellen M Ginzler, Joan T Merrill, Richard A Furie, William Stohl, W Winn Chatham, Arthur Weinstein, James D McKay, W Joseph McCune, Michelle Petri, James Fettiplace, David A Roth, Beulah Ji, Amy Heath
OBJECTIVE: Investigate long-term safety and efficacy of intravenous (IV) belimumab plus standard systemic lupus erythematosus (SLE) therapy (SoC) in active, autoantibody-positive SLE. METHODS: This was a multicenter, open-label, continuation study of IV belimumab given every four weeks with SoC in patients with SLE who completed a Phase II, double-blind study. Adverse events (AEs) and laboratory data were monitored from the first belimumab dose (in either study) until 24 weeks after the final dose...
February 16, 2019: Arthritis & Rheumatology
Huiming Wang, Changxuan Liu, Wenli Chen, Guohua Ding
CD19+ CD24hi CD38hi cells play an essential role in maintaining immune homeostasis. CD40 signaling is involved in regulating the induction and function of CD19+ CD24hi CD38hi cells. Changes in B-cell subpopulations and CD19+ CD24hi CD38hi cells have been observed in systemic lupus erythematosus (SLE) patients. Whether changes in the B-cell subpopulation are related to the aberrant CD40 signaling in SLE patients remains unclear. In this study, we examined changes in the levels of CD19+ CD24hi CD38hi cells and CD19+ CD24hi CD38low cells in peripheral blood mononuclear cells and the serum level of soluble CD40 ligand (sCD40L) in 30 patients with SLE...
February 16, 2019: Journal of Cellular Biochemistry
Eun Hye Park, Vibeke Strand, Yoon Jeong Oh, Yeong Wook Song, Eun Bong Lee
BACKGROUND: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and the involvement of multiple internal organs. Previous studies reported poorer health-related quality of life (HRQoL) in patients with SSc compared with the general population. However, very little is known about how HRQoL in SSc patients compares with that in patients with other systemic autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sjogren's syndrome (SjS)...
February 15, 2019: Arthritis Research & Therapy
Qiao-Mei Xie, Qiu-Yue Lou, Shun-Wei Huang, Hua-Qing Hu, Su-Su Li, Man Zhang, Xiu-Xiu Sun, Jian-Hua Xu, Shan-Qun Jiang, Sheng-Xiu Liu, Sheng-Qian Xu, Jing Cai, Shuang Liu, Fa-Ming Pan, Jin-Hui Tao, Long Qian, Chun-Huai Wang, Chun-Mei Liang, Hai-Liang Huang, Hai-Feng Pan, Hong Su, Yan-Feng Zou
OBJECTIVES: The aim of this study is to investigate whether heat shock protein 70 (Hsp70) gene polymorphisms are implicated in systemic lupus erythematous (SLE) susceptibility, the efficacy of glucocorticoids (GCs) treatment, and improvement of health-related quality of life. METHODS: A total of 499 SLE patients and 499 controls were included in a case-control study, and 468 SLE patients treated with GCs for 12 weeks were involved in a follow-up study. Patients who completed the 12-week follow-up were divided into GCs-sensitive and GCs-insensitive group by using the SLE disease activity index...
February 13, 2019: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
Yi Li Wong, Mei-Tzu Su, Akiko Sugahara-Tobinai, So Itoi, Dai Kezuka, Shota Endo, Masanori Inui, Toshiyuki Takai
Immune homeostasis is critically regulated by the balance between activating and inhibitory receptors expressed on various immune cells such as T and B lymphocytes, and myeloid cells. The inhibitory receptors play a fundamental role in the immune-checkpoint pathway, thus maintaining peripheral tolerance. We recently found that expression of leukocyte immunoglobulin-like receptor (LILR)B4, an inhibitory member of the human LILR family, is augmented in autoantibody-producing plasmablasts/plasma cells of systemic lupus erythematosus (SLE) patients...
February 15, 2019: International Immunology
Elizabeth A Blakeway, Noha Elshimy, Andrew Muinonen-Martin, Maria Marples, Bipin Mathew, Angana Mitra
Checkpoint blockade immunotherapy has revolutionized the treatment of advanced melanoma, with impressive survival benefits attained through upregulation of the anticancer immune response. Blockade of regulatory checkpoint molecules can, however, also result in aberrant immune activation leading to undesirable inflammation and autoimmunity. Although many genetic determinants have been described in patients with primary autoimmune diseases, it is uncertain whether patients developing autoimmune skin disease as an adverse effect of anti-PD-1 therapy share the same genetic risks...
February 11, 2019: Melanoma Research
Hakan Babaoğlu, Ata Baytaroğlu, Murat Torğutalp, Abdulsamet Erden, Sibel Kadayıfçılar, Umut Kalyoncu
Background/aim: We aimed to assess the association between retinal vascular caliber (RVC) scores and disease activity in rheumatoid arthritis (RA) patients. Materials and methods: Forty-seven RA patients, 32 systemic lupus erythematosus (SLE) patients, and 45 healthy people were enrolled. RA and SLE patients were subdivided into groups according to C-reactive protein (CRP) levels. RA patients were also grouped according to Disease Activity Score-28 (DAS-28). Fundus photography was performed for all patients...
February 11, 2019: Turkish Journal of Medical Sciences
Vasil V Vasilev, Maria Radanova, Valentin J Lazarov, Marie-Agnes Dragon-Durey, Veronique Fremeaux-Bacchi, Lubka T Roumenina
The complement component C3 is at the heart of the complement cascade. It is a complex protein, which generates different functional activated fragments (C3a, C3b, iC3b, C3c, C3d). C3b is a constituent of the alternative pathway C3 convertase (C3bBb), binds multiple regulators, and receptors, affecting thus the functioning of the immune system. The activated forms of C3 are a target for autoantibodies. This review focuses on the discovery, disease relevance, and functional consequences of the anti-C3b autoantibodies...
2019: Frontiers in Immunology
E Garcia-Vives, C Solé, T Moliné, A M Alvarez-Rios, M Vidal, I Agraz, J Ordi-Ros, J Cortés-Hernández
BACKGROUND: Antibodies to M-type phospholipase A2 receptor (a-PLA2 R) have been identified in most patients with idiopathic membranous nephropathy, but the prevalence in membranous lupus nephritis (MLN) is still unclear. The objective of this study was to assess the prevalence of a-PLA2 R antibodies in a large cohort of patients with lupus nephritis. METHODS: a-PLA2 R antibodies were measured by ELISA in serum from patients with systemic lupus erythematosus ( n = 190), of whom 37 had a biopsy-proven MLN...
February 13, 2019: Lupus
Elaine F Kenny, Bärbel Raupach, Ulrike Abu Abed, Volker Brinkmann, Arturo Zychlinsky
Systemic lupus erythematosus (SLE) is an autoimmune disease that has high morbidity and can result in multi-organ damage. SLE is characterized by dysregulated activation of T- and B-lymphocytes and the production of autoantibodies directed against nuclear components. The endonuclease deoxyribonuclease 1 (DNase1) is abundant in blood and a subset of SLE patients have mutations in DNASE1. Furthermore, a report showed that Dnase1-deficient mice develop an SLE-like disease, but these mice also carry a deletion of the gene adjacent to Dnase1, which encodes the chaperone TRAP1/HSP75...
February 13, 2019: European Journal of Immunology
Alaa A A Mohamed, Nevin Hammam, Mona H El Zohri, Tamer A Gheita
Objectives: This study aims to correlate subclinical echocardiographic features with the clinical, laboratory, and therapeutic profiles of the patients to characterize risks for systemic lupus erythematosus (SLE) cardiac diseases. Methods: The study included 59 SLE patients. Demographic data, disease characteristics, and current therapies were recorded, and the anthropometric measurements and routine laboratory tests were performed. The disease activity by the SLE Disease Activity Index-2K (SLEDAI2K) and the presence of metabolic syndrome (MetS) were assessed...
2019: BioMed Research International
Nandakrishna Bolanthakodi, Sudha Vidyasagar, Muralidhar Varma, Avinash Holla
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity described by Hinchey et al in late 90's, characterised by variable associations of seizure activity, consciousness impairment ranging from confusion to coma, headaches, visual abnormalities, nausea/vomiting and focal neurological signs. Common causes are accelerated hypertension, eclampsia, preeclampsia, cytotoxic drug use and autoimmune diseases like systemic lupus erythematosus.We report a case of PRES in a 62-year-old female patient due to hypercalcemia secondary to vitamin D toxicity on treatment with calcium supplements and vitamin D for secondary hypoparathyroidism...
February 11, 2019: BMJ Case Reports
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"